VIVUS, Inc. (NASDAQ:VVUS) Files Supplementary Application


Dallas, Texas 02/14/2014 (FINANCIALSTRENDS) – The $693 million market capped drug maker VIVUS, Inc. (NASDAQ:VVUS) announced in the last week of February that the regulator U.S. Food and Drug Administration has acceded to its request and given its in principal approval to file a follow up add on application which adds clinical data to its previously submitted application seeking approval for its drug candidate “STENDRA(TM) (avanafil).” The new data contains updated “efficacy and safety” information which has been collected from its ongoing “study TA-501” which had been published under the header “A Randomized, Double-Blind, Placebo-Controlled Evaluation of Avanafil for On-Demand Treatment of Men with Erectile Dysfunction” previously. The due date for additional filing on this application is late September 2014.

It is appropriate to note here that VIVUS, Inc. (NASDAQ:VVUS) had in the past disclosed positive outcomes from its  multi centre study whose end result was to determine the efficacy and the safety parameters to be followed if the target drug “STENDRA” had to be administered in two doses separated by 15 minutes. The study involved 440 patients being enrolled in study centres across 30 locations across U.S. The results showed that the patients who had been administered the target drug were showing substantially improved recovery when compared against the treatment rates of existing lotions in obtaining erections. The USP of the target drug is that it is found to be effective to cause erection with the application of the balm just 10 minutes with a 200 mg dose, where as it took 12 minutes for the erection to be caused for a 100 mg dose. Other drugs in the market today have a prescribed time limit of 30 minutes before intercourse application for them to be effective. On the back of this update, the stock was up 6 percent during trading this week.

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.